Emerging bispecific and trispecific antibodies offer promise for advanced and tailored medical treatments.

From GlobeNewswire: 2025-04-04 11:48:00

Over the past two decades, immunotherapy has revolutionized medical treatments with monoclonal antibodies targeting specific antigens. Bispecific and trispecific antibodies are now emerging as advanced therapies, promising improved efficacy and safety. The bispecific antibody market is estimated at US$12 billion in 2024, projected to reach US$50 billion by 2030.

Trispecific antibodies go a step further by targeting three antigens simultaneously, showing promising preclinical efficacy. For example, ISB2001 has demonstrated superior tumor reduction in animal models compared to bispecific antibodies. This approach could address challenges like tumor heterogeneity and immune evasion, enhancing treatment outcomes.

Bispecific and trispecific antibodies, initially developed for cancer treatment, are now being explored for autoimmune, inflammatory diseases, neurodegenerative diseases, and viral infections. Their potential to simultaneously target multiple immune factors offers promise for more effective and tailored therapies across various medical conditions. Research is ongoing to expand their applications and improve treatment options.



Read more at GlobeNewswire: Bispecific Trispecific Antibodies Market Size FDA Approval